rivaroxaban oral suspension — Medica
Thromboprophylaxis in a patient with congenital heart disease after the Fontan procedure
Initial criteria
- Patient is age ≥ 2 years and < 18 years
- Patient has undergone the Fontan procedure
- If rivaroxaban oral suspension is being requested, patient is unable to have Xarelto tablets appropriately administered OR prescribed dose cannot be achieved by Xarelto 10 mg, 15 mg, or 20 mg tablets
Approval duration
1 year